Sigma Planning Corp’s Grace Therapeutics GRCE Stock Holding History

Sigma Planning Corp’s Portfolio GRCE Stock Details GRCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-215	Closed	-$19K	–	1120
2019 Q3	$19K	Buy	+215	New	+$19.9K	﹤0.01%	990

Other funds holding GRCE

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Peconic Partners New York $5.78B AUM 127.23% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Sigma Planning Corp's GRCE Position: Q4 2019 in Review

Sigma Planning Corp sold out of Grace Therapeutics (GRCE) in Q4 2019, closing a stake of 215 shares — an estimated $19K sold.

Sigma Planning Corp first reported a position in GRCE in Q3 2019 and held it in 1 quarter. The position peaked at $19K in Q3 2019. 33 funds tracked by Wall St. Rank hold GRCE as of Q4 2019.

Sigma Planning Corp reported no remaining Grace Therapeutics position as of Q4 2019 after selling out during the quarter.
Sigma Planning Corp sold 215 Grace Therapeutics shares in Q4 2019, an estimated $19K.
Sigma Planning Corp first reported a position in Grace Therapeutics in Q3 2019 and held it in 1 quarter.
Sigma Planning Corp's Grace Therapeutics position peaked at $19K in Q3 2019.
33 funds tracked by Wall St. Rank held Grace Therapeutics as of Q4 2019.

Based on Sigma Planning Corp's 13F filing for Q4 2019, filed 3 Feb 2020.